- Illumina | Sequencing and array solutions to fuel genomic discoveries
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics
- Does Illumina’s 20% Surge Signal a Reversal After GRAIL Divestiture News?
News surrounding Illumina’s ongoing antitrust legal battles and recent strategic shifts, such as updates on the planned divestiture of GRAIL, have kept investors on edge These major headlines
- About Us | A global leader in genomics - Illumina
We are Illumina We are a global genomics and human health leader innovating the future of precision health We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health
- Statement Regarding Illumina’s Decision to Divest Grail
Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives
- Illumina - Wikidata
Illumina (Q2068984) American company that develops systems for the analysis of genetic variation Illumina, Inc ILMN edit
- Illumina, Inc. $ILMN Stock Position Lifted by JPMorgan Chase Co.
JPMorgan Chase Co grew its position in Illumina, Inc (NASDAQ:ILMN - Free Report) by 7 7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission The fund owned 708,444 shares of the life sciences company's stock after acquiring an additional
- Genomics products | Illumina
Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications
- Illumina, Inc. - Investors
A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments
|